ORIGINAL ARTICLE

Hemoglobin A1c and C-reactive protein are independently associated with blunted nocturnal blood pressure dipping in obesity-related prediabetes

Abbi D Lane-Cordova[1,2], Graziela Z Kalil[1], Christopher J Wagner[1], Amy L Sindler[1], Jess G Fiedorowicz[3,4,5,6], Tiwaloluwa Ajibewa[1], William G Haynes[4,6,9] and Gary L Pierce[1,6,7,8]

Blunted nocturnal dipping in blood pressure (BP) is associated with increased cardiovascular disease (CVD) risk in middle-aged/older adults. The prevalence of blunted nocturnal BP dipping is higher in persons with obesity and diabetes, conditions that are also associated with elevated aortic stiffness and inflammation. Therefore, we hypothesized that elevated glycemia, inflammation and aortic stiffness would be inversely associated with the magnitude of nocturnal systolic BP dipping among middle-aged/older adults with obesity at high CVD risk. Twenty-four hour ambulatory BP monitoring, aortic stiffness (carotid–femoral pulse wave velocity, CF-PWV), hemoglobin A1c (HbA1c) and inflammation (C-reactive protein, CRP) were measured in 86 middle-aged/older adults with obesity and at least one other CVD risk factor (age 40–74 years; 34 male/52 female; body mass index $= 36.7 \pm 0.5$ kg m^{-2}; HbA1c $= 5.7 \pm 0.04\%$). In the entire cohort, CRP ($\beta = 0.40 \pm 0.20$, $P = 0.04$), but not HbA1c or CF-PWV was independently associated with systolic BP dipping percent (Model $R^2 = 0.07$, $P = 0.12$). In stratified (that is, presence or absence of prediabetes) multiple linear regression analysis, HbA1c ($\beta = 6.24 \pm 2.6$, $P = 0.02$) and CRP ($\beta = 0.57 \pm 0.2$, $P = 0.01$), but not CF-PWV ($\beta = 0.14 \pm 2.6$, $P = 0.74$), were independently associated with systolic BP dipping percent (Model $R^2 = 0.32$, $P < 0.01$) in obese adults with prediabetes but were absent in obese adults without prediabetes (Model $R^2 = 0.01$ $P = 0.95$). However, nocturnal systolic BP dipping percent ($P = 0.65$), CF-PWV ($P = 0.68$) and CRP ($P = 0.59$) were similar between participants with and without prediabetes. These data suggest that impaired long-term glycemic control and higher inflammation may contribute partly to blunted BP dipping in middle-aged/older adults with obesity-related prediabetes.
Hypertension Research (2018) 41, 33–38; doi:10.1038/hr.2017.82; published online 26 October 2017

INTRODUCTION

A decline in systolic blood pressure (BP) $\geqslant 10\%$ at night during sleep is a normal physiological phenomenon referred to as nocturnal BP 'dipping'. A blunted decline in nocturnal systolic BP (that is, 'non-dipping') is associated with target organ damage such as increased left ventricular mass and central arterial stiffness[1–3] and heightened cardiovascular disease (CVD) mortality, independent of average 24 h systolic BP.[4] However, the mechanisms underlying blunted nocturnal systolic BP dipping remain unclear.

The nocturnal non-dipping BP pattern is more prevalent in obesity[5] and the prevalence of non-dipping in individuals with diabetes may be as high as 30%.[6] In addition, individuals with obesity are more likely to exhibit higher systemic inflammation compared with normal-weight adults.[7,8] This is important, because inflammation likely contributes to the development of CVD in obesity in part because of insulin resistance and vascular dysfunction including aortic stiffness,[8,9] a robust independent predictor of CVD risk in middle-aged/older adults.[10,11] Moreover, the combination of obesity and metabolic dysfunction results in the greatest risk for CVD and death, underscoring the importance of glycemic control for CVD risk management in obese adults with early stage type 2 diabetes (that is, prediabetes).[12]

Given that 86 million Americans have prediabetes,[13] more than double the number with diagnosed type 2 diabetes,[13,14] it is important to identify modifiable risk factors to attenuate CVD risk in this group. However, whether the prevalence of blunted nocturnal systolic BP dipping is higher in obese adults in the presence or absence of prediabetes is unknown. Furthermore, the intermediary mechanisms

[1]Department of Health and Human Physiology, University of Iowa, Iowa City, IA, USA; [2]Department of Exercise Science, Arnold College of Public Health, University of South Carolina, Columbia, SC, USA; [3]Department of Psychiatry, University of Iowa, Iowa City, IA, USA; [4]Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; [5]Department of Epidemiology, University of Iowa, Iowa City, IA, USA; [6]Abboud Cardiovascular Research Cente; [7]Center for Hypertension Research and [8]Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, USA
[9]Current address: AstraZenica, Inc., Bioscience Diabetes Department, AstraZenica Innovative Medicines and Early Development Unit, Gothenburg, Sweden.
Correspondence: Dr GL Pierce, Department of Health and Human Physiology, University of Iowa, 225 S Grand Avenue, 412 FH, Iowa City, IA 52242, USA.
E-mail: gary-pierce@uiowa.edu
Received 2 March 2017; revised 11 May 2017; accepted 7 June 2017; published online 26 October 2017

that might contribute to abnormal systolic BP dipping in obesity-related prediabetes have not been explored.

The purpose of the study was to determine whether systemic inflammation, recent glycemic control and aortic stiffness were independently associated with nocturnal BP dipping in a cohort of middle-aged/older adults with obesity and at high CVD risk. We hypothesized that elevated glycemia (hemoglobin A1c, HbA1c), inflammation (C-reactive protein, CRP) and aortic stiffness (carotid–femoral pulse wave velocity, CF-PWV) would be inversely associated with the magnitude of nocturnal systolic BP dipping (dipping percent) among middle-aged/older adults with obesity. Second, we also hypothesized that the associations between HbA1c, CRP and CF-PWV would be selective to obese persons with prediabetes. This is clinically important, because this would provide evidence that impaired long-term glycemic control, inflammation and arterial stiffness may contribute to blunted nocturnal systolic BP dipping, which has been linked to subclinical and overt CVD[1,2,4] in obesity.

METHODS

Study design
Ninety-nine middle-aged/older adults were recruited but complete data were available in 86 of these individuals (34 male/52 female) for analyses. The analyses used baseline data in 86 middle-aged/older adults (age 40–75 years) with obesity who were recruited as part of a pharmacological weight loss study (Clinical Trials.gov study NCT01351753) who had 24 h ambulatory BP monitoring done at baseline. Participants were included in the study if they were obese, defined as having a body mass index (BMI) $\geqslant 30$ kg m^{-2} and had at least one additional CVD risk factor such as hypertension, hyperlipidemia, hyperglycemia or metabolic syndrome, or who were being treated for a CVD risk factor with anti-hypertensive medications or anti-hyperlipidemia medications. Participants were excluded if they had a history of smoking cessation within the past 3 months, had a diagnosed atherosclerotic event within the past 6 months, had congestive heart failure (WHO class III or IV), had renal impairment defined as serum creatinine $\geqslant 1.4$ mg dl^{-1} (females) or $\geqslant 1.5$ mg dl^{-1} (males), or if they were currently involved in any weight loss or formal vigorous exercise program. All women were postmenopausal of whom eight were on hormone replacement therapy: transdermal patch and removed the patch 24 h before the experimental visit ($n = 3$); oral hormone replacement therapy and went off for 1 month before measurements ($n = 2$); and intravaginal cream or tablets for postmenopausal symptoms ($n = 3$). Fifteen participants were taking levothyroxine with doses ranging from 50 to 150 mcg per day and had normal TSH concentrations at time of study. The study was approved by the University of Iowa Institutional Review Board and all participants signed written informed consent.

Experimental visit
Participants reported to the University of Iowa Institute for Clinical and Translational Science Clinical Research Unit after an overnight 8 h fast. Height and weight were measured and a fasting venous blood sample was obtained. Following 15 min of supine rest, BP and aortic stiffness were measured (see below for details). Participants were fitted and started to wear a 24 h ambulatory BP monitor at the end of the visit and instructed to wear the monitor for 24 h. As a result of scheduling, in some instances participants wore the 24 h ambulatory BP monitor before the experimental visit.

Body mass index
Height and weight were measured with participants wearing a standard gown and no shoes and after participants emptied their bladder. Measurements were done using a stadiometer and a digital scale by a trained nurse. BMI was calculated by dividing weight (in kg) by height (in m^2).

Twenty-four hour ambulatory BP
Ambulatory BP monitoring was performed for 24 h with a cuff on the non-dominant arm, (Spacelabs Healthcare, Inc., Snoqualmie, WA, USA). Participants were instructed to record their activities and sleep periods for the 24 h monitoring period. BP was measured every 30 min during the day from 0600 to 2300 h and nighttime (that is, 'nocturnal') BP was recorded every 60 min from 2300 to 0600 h. Daytime and nocturnal BPs were determined from these fixed times. Participants had to have at least 10 daytime readings and 5 nighttime readings and at least 80% successful readings of planned measurements over the 24 h. The percent (%) of nocturnal systolic BP dipping was calculated as:

$$\frac{\text{Nocturnal systolic BP} - \text{Daytime systolic BP}}{\text{Daytime systolic BP}} \times 100\%$$

Aortic stiffness
CF-PWV, the 'reference standard' measurement of aortic stiffness, was obtained non-invasively by applanation tonometry (Sphygmocor, AtCor Medical, Inc., NSW, Australia) as previously described.[15,16] Electrocardiogram-gated pulse waveforms of the carotid, femoral and radial arteries were recorded sequentially and PWV was calculated as path length (L) divided by time delay (t) between sites (PWV = L/t). L was calculated as distance from the suprasternal notch to femoral minus the distance from the suprasternal notch to the carotid artery. The peak of the R wave from the simultaneously recorded electrocardiogram was used as a timing marker. Within-subject coefficient of variation for CF-PWV in our laboratory is 2.1% for nine adults measured on two visits separated by 1 week.

Circulating factors
Circulating concentrations of fasting insulin, glucose, HbA1C, cholesterol and triglycerides were measured in venous blood sample by the University of Iowa Diagnostic Laboratory by standard techniques. CRP was measured by the University of Iowa Diagnostic Laboratory by a high-sensitivity turbidimetric method with a minimal detection level of 0.2 mg l^{-1}. Prediabetes was defined as an HbA1C value $\geqslant 5.7$ and not being treated with any antidiabetic drugs. Homeostatic model of insulin resistance was calculated as follows: insulin (mU ml^{-1}) × glucose (mg dl^{-1})/405.

Risk of obstructive sleep apnea
As nocturnal BP and metabolic health[17] can be influenced by the presence of obstructive sleep apnea (OSA), we used the Berlin Survey to determine whether participants had high risk of OSA. This survey has been validated and used in other cohort studies. Briefly, participants were categorized as high or low risk for OSA based on their responses to questions regarding snoring, daytime sleepiness and CV risk factors as previously described.[18] Complete data on likelihood of OSA at the time of vascular measurements and ambulatory BP monitoring were available in 42 participants.

Statistics
Normality of distribution for variables of interest was assessed using Shapiro–Wilk tests. Differences between adults with and without prediabetes were evaluated using unpaired t-tests or Wilcoxon rank-sum tests for non-normally distributed variables and χ^2-tests for categorical variables. Univariate correlations of nocturnal systolic dipping percent and established CVD risk factors were assessed using Spearman's correlations. Associations between aortic stiffness, circulating factors and nocturnal systolic BP dipping were evaluated using multivariable regression, first in the entire cohort and then stratified by pre-diabetes status because of the well-characterized effect of diabetes on nocturnal systolic BP dipping.[19,20] A third multivariable model was constructed to adjust for known modifiers of BP and nocturnal dipping. We also tested for associations between these factors and average nocturnal systolic BP because nocturnal BP is associated with CVD and non-CVD mortality. A residuals versus fitted plot was constructed for each significant predictor variable to assess the assumptions of linearity and homoscedasticity. A sensitivity analysis was performed on a subset of participants that excluded those with possible undiagnosed diabetes (HbA1c $\geqslant 6.5\%$) and CRP level > 2 s.d. from the mean.

Significance was set at $P < 0.05$ and STATA version 14 (College Station, TX, USA) was used for all statistical analyses.

RESULTS

Participants

Characteristics of the cohort of the eighty-six individuals with obesity and at least 1 CVD risk factor (34 male/52 female) used for analyses are listed in Table 1. Thirty-eight percent of all participants were taking renin–angiotensin–aldosterone system antagonists. However, the proportion of participants taking renin–angiotensin–aldosterone system antagonists was the same (38%) in participants with and without prediabetes ($P = 1.00$).

Bivariate correlational and regression analyses in entire cohort

No traditional CVD risk factors significantly correlated with nocturnal systolic BP dipping percent in our cohort ($P > 0.13$ for all). Among our hypothesized predictors, CRP ($r = 0.25$, $P = 0.015$) but not CF-PWV ($r = 0.11$, $P = 0.29$) or HbA1c ($r = 0.13$, $P = 0.215$) was correlated with nocturnal systolic BP dipping in the entire cohort. In a multivariable analysis including CRP, HbA1c and CF-PWV conducted in the entire cohort, only CRP was associated with nocturnal systolic BP dipping percent ($\beta = 0.40$, $P = 0.04$) (Table 2).

Participants stratified by the presence or absence of prediabetes

Of the 86 participants, 50 had prediabetes, defined as HbA1C $\geqslant 5.7\%$ and not taking antidiabetic medication,[21] and 36 did not have prediabetes (Table 3). Participants with prediabetes were slightly older than participants without prediabetes ($P = 0.01$), but BMI did not differ by prediabetes status ($P = 0.59$). Clinic, daytime and nocturnal BP and CF-PWV were similar in adults with and without prediabetes (all $P > 0.05$, Table 3). Nocturnal systolic BP dipping percent was the same in adults with ($-10.5 \pm 6.4\%$) and without ($-9.9 \pm 6.1\%$) prediabetes ($P = 0.65$, Table 3). Three participants with prediabetes and one participant without prediabetes were 'risers', that is, their nocturnal systolic BP was higher than their daytime systolic BP and their dipping was positive. Four participants with prediabetes and one participant without prediabetes were extreme dippers; their systolic BP dipped $> 20\%$ at night. There was no difference in the proportion of participants with either pattern by prediabetes status ($P > 0.47$ for both comparisons).

Fourteen participants without prediabetes and 15 participants with prediabetes had high risk of OSA ($P = 0.12$ for difference between groups).

Bivariate correlational and regression analyses in participants with or without prediabetes

In individuals with prediabetes, CRP ($r = 0.34$, $P = 0.015$) and HbA1c ($r = 0.26$, $P = 0.05$), but not CF-PWV ($r = 0.09$, $P = 0.51$), were correlated with nocturnal systolic BP dipping percent in bivariate correlational analysis. In contrast, in individuals without prediabetes none of the hypothesized predictors correlated with nocturnal systolic BP dipping percent: CRP ($r = -0.15$, $P = 0.36$), HbA1c ($r = 0.01$, $P = 0.95$), CF-PWV ($r = -0.05$, $P = 0.79$). In the stratified unadjusted regression analysis with HbA1c, CRP and CF-PWV in the model, HbA1c ($\beta = 6.24$, $P = 0.02$) and CRP ($\beta = 0.57$, $P = 0.01$), but not CF-PWV ($\beta = 0.14$, $P = 0.74$), were independently associated with nocturnal systolic BP dipping percent in adults with prediabetes (Table 4A). These associations were absent in middle-aged/older adults without prediabetes (Table 4B). In a third stratified model in which we controlled for age, sex, average 24 h systolic BP, and anti-hypertensive and lipid-lowering medication usage, the associations between CRP ($\beta = 0.57$, $P = 0.12$) and HbA1c ($\beta = 7.35$, $P = 0.19$) with nocturnal systolic dipping percent remained significant (Table 4C).

To investigate whether indices of short-term glucose/insulin control or OSA were also associated with nocturnal systolic BP dipping percent, fasting insulin ($\beta = 0.32$, $P = 0.612$), fasting glucose ($\beta = 0.15$, $P = 0.267$) and fasting homeostatic model of insulin resistance ($\beta = -1.5$, $P = 0.571$) were not associated with nocturnal systolic BP dipping percent in the whole cohort, with similar findings in stratified analyses (Supplementary Table 1). OSA status was not associated with nocturnal systolic BP dipping percent in the whole cohort ($\beta = 0.35 \pm 2.2$, $P = 0.87$) or in stratified analyses.

As we had three statistical outliers (> 2 s.d. from the mean) for our CRP measurement, one individual with an extreme reverse dipping pattern ($+15\%$ compared with daytime systolic BP) and two individuals with HbA1c $> 6.5\%$, the cutoff for diabetes, we conducted a sensitivity analysis by performing the regression with these individuals omitted ($n = 80$, 35 without prediabetes and 45 with prediabetes). Our results remained the same: HbA1c ($\beta = 9.87$, $P = 0.027$) and CRP ($\beta = 0.97$, $P = 0.006$) but not CF-PWV ($\beta = 0.02$, $P = 0.96$), were independently associated with nocturnal systolic BP dipping percent in adults with prediabetes (Model $R^2 = 0.26$, $P = 0.006$). These associations remained absent in adults without prediabetes, neither HbA1c ($\beta = -2.38$, $P = 0.41$), CRP ($\beta = 0.07$, $P = 0.78$), nor CF-PWV ($\beta = 0.16$, $P = 0.71$) associated with nocturnal dipping percent (Model $R^2 = 0.03$, $P = 0.82$).

There was no association between clinic systolic BP and nocturnal systolic dipping percent ($\beta = 0.14 \pm 0.04$, $P = 0.76$). Finally, to test whether CRP, HbA1c and CF-PWV were also associated with average nocturnal systolic BP, in a multivariable model including age, sex, BMI, anti-hypertensive medication usage, CRP, HbA1c and CF-PWV, only CF-PWV was associated with average nocturnal systolic BP;

Table 1 Participant characteristics

n	86
Age (years)	56 ± 1
Female, n (%)	52 (60)
Prediabetes, n (%)	50 (58)
BMI (kg m^{-2})	36.7 ± 0.5
Clinic SBP (mm Hg)	128 ± 2
Clinic DBP (mm Hg)	73 ± 1
24 Hour ABPM daytime SBP (mm Hg)	126 ± 1
24 Hour ABPM nocturnal SBP (mm Hg)	114 ± 1
Antihypertensive medication, n (%)	60 (70)
Lipid-lowering medication, n (%)	31, 36
Nocturnal systolic BP dipping (%)	-10 ± 1
CF– PWV (m s^{-1})	9.2 ± 0.2
HbA1c (%)	5.7 ± 0.4
CRP (mg l^{-1})	4.0 ± 0.4
Total cholesterol (mg dl^{-1})	197 ± 4
LDL-C (mg dl^{-1})	116 ± 4
HDL-C (mg dl^{-1})	55 ± 2
Triglycerides (mg dl^{-1})	142 ± 7
Insulin (mcU ml^{-1})	15 ± 1
Fasting glucose (mg dl^{-1})	97 ± 1
HOMA-IR	3.6 ± 0.2
High risk of OSA, n (%)	29 (34)

Abbreviations: ABPM, ambulatory blood pressure monitoring; BMI, body mass index; BP, blood pressure; CF–PWV, carotid–femoral pulse wave velocity; CRP, C-reactive protein; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostatic model of insulin resistance; LDL, low-density lipoprotein; OSA, obstructive sleep apnea; SBP, systolic blood pressure.
Data are mean $\pm$ s.e. or n (%).

Table 2 Multivariable associations between nocturnal systolic blood pressure dipping percent and hemodynamic and clinical variables in entire cohort

Predictor	β (s.e.)	P-value
HbA1c (%)	1.80 (1.7)	0.28
CRP (mg l^{-1})	0.40 (0.2)	0.04*
CF–PWV (m s^{-1})	−0.02 (0.4)	0.99
		Model $R^2 = 0.07$, $P = 0.12$

Abbreviations: B, unstandardized regression coefficient; BP, blood pressure; CF–PWV, carotid–femoral pulse wave velocity; CRP, C-reactive protein; HbA1c, hemoglobin A1c.
*$P < 0.05$ variable significantly associated with nocturnal systolic blood pressure dipping percent.

Table 3 Clinical characteristics of study participants stratified by prediabetes status

	No prediabetes (n = 36)	Prediabetes (n = 50)	P-value
Age (years)	53 ± 1	57 ± 1*	0.01
Female, n (%)	23 (68)	29 (58)	0.48
BMI (kg m^{-2})	36.4 ± 0.9	37.0 ± 0.6	0.59
Clinic SBP (mm Hg)	130 ± 3	127 ± 2	0.40
Clinic DBP (mm Hg)	74 ± 2	72 ± 1	0.19
24 Hour ABPM daytime SBP (mm Hg)	129 ± 1	125 ± 2	0.06
24 Hour ABPM nocturnal SBP (mm Hg)	116 ± 2	111 ± 2	0.07
Anti-hypertensive medication, n (%)	27 (65)	33 (61)	0.72
Nocturnal SBP dipping (%)	−9.9 ± 1	−10.5 ± 1	0.64
Nocturnal non-dippers, n (%)	16 (39)	27 (48)	0.37
CF–PWV (m s^{-1})	9.1 ± 0.2	9.3 ± 0.3	0.82
HbA1c (%)	5.40 ± 0.04	5.95 ± 0.05*	<0.001
CRP (mg l^{-1})	3.6 ± 0.4	4.3 ± 0.6	0.58
Total cholesterol (mg dl^{-1})	201 ± 6	196 ± 6	0.10
LDL-cholesterol (mg dl^{-1})	116 ± 6	116 ± 5	0.27
HDL-cholesterol (mg dl^{-1})	57 ± 4	52 ± 2	0.63
Triglycerides (mg dl^{-1})	136 ± 10	147 ± 9	0.47
Insulin (mU ml^{-1})	12 ± 1.0	17 ± 1*	<0.01
Glucose (mg dl^{-1})	94 ± 1	99 ± 2*	0.04
HOMA-IR	2.76 ± 0.25	4.25 ± 0.37*	<0.01
High risk for OSA, n (%)	14 (39)	15 (30)	0.12

Abbreviations: ABPM, ambulatory blood pressure monitoring; BMI, body mass index; BP, blood pressure; CF–PWV, carotid–femoral pulse wave velocity; CRP, C-reactive protein; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostatic model of insulin resistance; LDL, low-density lipoprotein; OSA, obstructive sleep apnea; SBP, systolic blood pressure.
Data are mean ± s.e. *$P < 0.05$ vs. prediabetes.

$\beta = 1.97 \pm 0.8$, $P = 0.01$ in the whole cohort, driven by the prediabetes group in stratified analyses (Supplementary Table 2).

DISCUSSION

The primary findings of the current study are that higher HbA1c and circulating CRP concentrations are independently associated with less nocturnal systolic BP dipping percent only in individuals with obesity and prediabetes even after adjusting for age, sex, average 24 h systolic BP and anti-hypertensive medication usage. There was no relation between systolic BP dipping percent with short-term indices of glycemia (fasting glucose) or insulin resistance (fasting insulin and homeostatic model of insulin resistance) among obese adults without prediabetes. These findings suggest that CVD risk conferred by impaired longer-term glycemic control (HbA1c) not only directly contributes to elevated arterial stiffening and daytime BP as previously described,[22] but that elevated glycemia may also interfere with normal physiological nocturnal BP dipping in obesity. Furthermore, these results indicate that once middle-aged/older adults with obesity have prediabetes, small incremental increases in HbA1c may be associated with significantly more blunting of nocturnal systolic BP dipping compared with those without prediabetes. It reasons that even small improvements in HbA1c may improve nocturnal systolic BP dipping in middle-aged/older persons with obesity-related prediabetes. The study also supports the role of systemic inflammation as either a mediator of blunted nocturnal BP dipping or an identifier of overall higher risk among this sub-group of obese adults with prediabetes. Thus, whether reducing systemic inflammation would also attenuate blunted nocturnal systolic BP dipping in this group will require additional studies to test these hypotheses.

Blunted nocturnal systolic BP dipping is more common in persons with obesity[5] and the prevalence of blunted nocturnal systolic BP dipping in type 2 diabetes is over 30%.[6] Nighttime systolic BP is also predictive of CVD mortality in individuals with diabetes,[23] but whether this is true for adults with prediabetes is unclear. Surprisingly, in the current cohort we found that the nocturnal BP dipping percent was not different between obese adults with and without prediabetes. However, among the obese persons with prediabetes defined as an HbA1C ⩾ 5.7%, HbA1C was independently associated with blunted nocturnal systolic BP dipping ($\beta = 7.35$, $P = 0.010$), suggesting that impaired long-term glycemic control may affect systolic BP dipping in obese persons with prediabetes. Consistent with this, biomarkers associated with short-term glucose control (for example, fasting glucose, insulin and HOMA) were not associated with nocturnal systolic BP dipping in our whole cohort or by prediabetes status. This suggests that longer-term and not short-term glycemic control potentially modulates nocturnal systolic BP dipping in obese adults with prediabetes. This finding is not entirely unexpected as short-term biomarkers are highly variable and may be affected by the patient's recent dietary intake, physical activity or length of fasting.

Circulating CRP, a biomarker of systemic inflammation and CVD risk, is elevated in persons with obesity.[24] In addition, higher CRP is associated with increased arterial stiffness in middle-aged/older adults[25] that are both elevated in individuals with obesity.[24] Anti-inflammatory therapy is associated with reductions in aortic stiffness and aortic inflammation supporting the idea that inflammation has a key role in aortic remodeling and stiffness.[26] Arterial stiffness is associated with less nocturnal systolic BP dipping among adults with hypertension,[1,27] but before our study it was unknown whether higher inflammation and arterial stiffness could be potential intermediary mechanisms that modulate alterations in nocturnal BP dipping among older adults with obesity. Taken together, our results and others indicate that systemic inflammation among obese adults with pre-diabetes may be one intermediary mechanism for blunted nocturnal BP dipping, but prospective studies with follow-up or anti-inflammatory intervention studies will be needed to confirm this finding.

Because of the association of average nocturnal systolic BP and CVD risk, we investigated whether HBA1c, CRP and CF-PWV were associated with average nocturnal systolic BP itself (as opposed to just percent dipping). There was an independent association between aortic stiffness and average nocturnal systolic BP, independent of age and BMI. Given that aortic stiffness has been purported to precede incident hypertension, and aortic stiffness improves risk prediction for

Table 4 Minimally adjusted associations between nocturnal systolic blood pressure dipping percent and hypothesized predictors in obese middle-aged/older adults with prediabetes (A) and without prediabetes (B)

Predictor	β (s.e.)	P-value
A. Prediabetes		
HbA1c (%)	6.24 (2.6)	0.02*
CRP (mg l⁻¹)	0.57 (0.2)	0.01*
CF–PWV (m s⁻¹)	0.14 (0.4)	0.74
		Model $R^2=0.22$ $P=0.009*$
B. No prediabetes		
HbA1c (%)	0.43 (4.5)	0.93
CRP (mg l⁻¹)	0.00 (0.4)	0.99
CF–PWV (m s⁻¹)	−0.37 (0.7)	0.58
		Model $R^2=0.01$ $P=0.95$
C. Multivariable adjusted associations between hypothesized predictors and nocturnal SBP dipping percent in middle-aged/older adults with prediabetes		
HbA1c (%)	7.59 (2.8)	0.01*
CRP (mg l⁻¹)	0.58 (0.2)	0.02*
Age (years)	−0.04 (0.01)	0.79
Sex (male)	−1.07 (2.2)	0.64
BMI (kg m⁻²)	0.03 (0.2)	0.89
Average 24 h SBP (mm Hg)	−0.03 (0.07)	0.67
Lipid-lowering medication treatment (yes/no)	−1.76 (2.2)	0.42
Antihypertension medication treatment (yes/no)	0.38 (2.0)	0.85
		Model $R^2=0.27$ $P=0.03*$

Abbreviations: B, unstandardized regression coefficient; BMI, body mass index; CF–PWV, carotid–femoral pulse wave velocity; CRP, C-reative protein; HbA1c, hemoglobin A1c; SBP, systolic blood pressure.
*$P<0.05$ variable or model significantly associated with nocturnal dipping percent.

CVD events in models with traditional CVD risk factors, these results are not unprecedented.[11,28] There was no association between clinical systolic BP and nocturnal dipping in our study, underscoring the importance of monitoring 24 h BP to assess CVD risk. Our study suggests that higher aortic stiffness may contribute to overall CVD risk in part through its influence on nocturnal BP, but further studies are required to test this hypothesis.

A limitation of our study is the use of data collected at a single time point in a relatively small sample. This may have limited our ability to detect small to mid-sized effects. We included information regarding the likelihood of sleep apnea in our study, but we did not obtain this measurement on all participants. Therefore, we may not have captured the true prevalence of sleep apnea in our cohort. The cross-sectional design does not allow us to determine cause and effect between HbA1c or CRP with nocturnal systolic BP dipping in the cohort with prediabetes. Longitudinal data would be useful to assess how changes in HbA1c and CRP at multiple time points alter nocturnal systolic BP dipping profiles within the same person. We are unable to determine whether blunted nighttime systolic BP dipping is associated with mortality in obese persons with prediabetes; therefore, this should be examined in future investigations in prospective studies. Lastly, we did not record the timing of anti-hypertensive medication usage although most participants likely take the medications in the morning. Whether or not participants took medication immediately before bedtime may have affected their nocturnal BP. A strength of our study is the similarity of the well characterized cohort of persons with obesity at high CVD risk and multivariable stratified models adjusting for important confounders.

In conclusion, in middle-aged/older adults with obesity and at least one other CVD risk factor, higher HbA1c and CRP are independently associated with less nocturnal systolic BP dipping selectively among those persons with prediabetes (defined by elevated HbA1c). Prediabetes status itself did not affect the magnitude of nocturnal systolic BP dipping among obese adults. Our study has demonstrated that longer-term glycemic control and inflammation may contribute to CVD risk through their association with nocturnal BP dipping. Future studies are needed to determine if improvements in HbA1c and CRP in early stages of type 2 diabetes may improve normal physiological dipping of nighttime systolic BP and decrease CVD risk in this high-risk group.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

1 Cicek Y, Durakoglugil ME, Kocaman SA, Cetin M, Erdogan T, Dogan S, Ugurlu Y, Canga A. Non-dipping pattern in untreated hypertensive patients is related to increased pulse wave velocity independent of raised nocturnal blood pressure. *Blood Pressure* 2013; **22**: 34–38.
2 Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Non-dipping pattern and subclinical cardiac damage in untreated hypertension: a systematic review and meta-analysis of echocardiographic studies. *Am J Hypertens* 2015; **28**: 1392–1402.

3 O'Flynn AM, Madden JM, Russell AJ, Curtin RJ, Kearney PM. Isolated nocturnal hypertension and subclinical target organ damage: a systematic review of the literature. *Hypertens Res* 2015; **38**: 570–575.

4 Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. *J Hypertens* 2002; **20**: 2183–2189.

5 Ben-Dov IZ, Bursztyn M. Ambulatory blood pressure monitoring in childhood and adult obesity. *Curr Hypertens Rep* 2009; **11**: 133–142.

6 Fogari R, Zoppi A, Malamani GD, Lazzari P, Destro M, Corradi L. Ambulatory blood pressure monitoring in normotensive and hypertensive type 2 diabetes. Prevalence of impaired diurnal blood pressure patterns. *Am J Hypertens* 1993; **6**: 1–7.

7 Debnath M, Agrawal S, Agrawal A, Dubey GP. Metaflammatory responses during obesity: pathomechanism and treatment. *Obes Res Clin Pract* 2016; **10**: 103–113.

8 Isomaa B. A major health hazard: the metabolic syndrome. *Life Sci* 2003; **73**: 2395–2411.

9 Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. *Yonsei Med J* 2012; **53**: 258–261.

10 Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, Laurent S, Maldonado J, Mitchell GF, Najjar SS, Newman AB, Ohishi M, Pannier B, Pereira T, Vasan RS, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang KL, Webb DJ, Willum Hansen T, Zoungas S, McEniery CM, Cockcroft JR, Wilkinson IB. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17 635 subjects. *J Am Coll Cardiol* 2014; **63**: 636–646.

11 Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation* 2010; **121**: 505–511.

12 Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. *Int J Cardiol* 2013; **168**: 4761–4768.

13 Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. In: *Services USDoHaH*, ed. U.S. Department of Health and Human Services: Atlanta, GA; 2014.

14 Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. *JAMA* 2015; **314**: 1021–1029.

15 Lane AD, Yan H, Ranadive SM, Kappus RM, Sun P, Cook MD, Harvey I, Woods J, Wilund K, Fernhall B. Sex differences in ventricular-vascular coupling following endurance training. *Eur J Appl Sci* 2014; **114**: 2597–2606.

16 Pierce GL, Zhu H, Darracott K, Edet I, Bhagatwala J, Huang Y, Dong Y. Arterial stiffness and pulse-pressure amplification in overweight/obese African-American adolescents: relation with higher systolic and pulse pressure. *Am J Hyprtens* 2013; **26**: 20–26.

17 Shimizu I, Yoshida Y, Minamino T. A role for circadian clock in metabolic disease. *Hypertens Res* 2016; **39**: 483–491.

18 Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Int Med* 1999; **131**: 485–491.

19 Ayala DE, Moya A, Crespo JJ, Castineira C, Dominguez-Sardina M, Gomara S, Sineiro E, Mojón A, Fontao MJ, Hermida RC. Hygia Project Investigators. Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes. *Chronobiol Int* 2013; **30**: 99–115.

20 Cuspidi C, Vaccarella A, Leonetti G, Sala C. Ambulatory blood pressure and diabetes: targeting nondipping. *Curr Diabetes Rev* 2010; **6**: 111–115.

21 American Diabetes Association. 2. Classification and diagnosis of diabetes. *Diabetes Care* 2016; **39**(Suppl 1): S13–S22.

22 Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. *Diabetes Obes Metab* 2015; **17**: 1180–1193.

23 Draman MS, Dolan E, van der Poel L, Tun TK, McDermott JH, Sreenan S, O'Brien E. The importance of night-time systolic blood pressure in diabetic patients: Dublin Outcome Study. *J Hypertens* 2015; **33**: 1373–1377.

24 Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 1999; **282**: 2131–2135.

25 Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. *Arterioscl Thromb Vasc Biol* 2004; **24**: 969–974.

26 Wang S, Ma AQ, Song SW, Quan QH, Zhao XF, Zheng XH. Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. *Eur J Clin Nutr* 2008; **62**: 1426–1431.

27 Castelpoggi CH, Pereira VS, Fiszman R, Cardoso CR, Muxfeldt ES, Salles GF. A blunted decrease in nocturnal blood pressure is independently associated with increased aortic stiffness in patients with resistant hypertension. *Hypertens Res* 2009; **32**: 591–596.

28 Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. *JAMA* 2012; **308**: 875–881.